{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-050606","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-11-09T11:30:34+00:00","discovered_at":"2026-11-09T11:35:00.256513+00:00","generated_at":"2026-11-09T11:35:25.983681+00:00","sec_items":["1.01","2.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Abeona acquires Ellodi's APT-1011 (ABO-801) for $20M stock plus up to $60M milestones; raises $30M PIPE","bullets":["Acquired APT-1011 (renamed ABO-801), a once-daily oral fluticasone propionate ODT for eosinophilic esophagitis; $20M paid in 4,494,383 ABEO shares, no upfront cash.","Ellodi eligible for $30M on FDA NDA approval and up to $30M in sales milestones, plus low-to-mid-teens royalties; 4,494,383 shares locked up 1/3 at 6, 12, 18 months.","Private placement: 6,400,000 shares at $3.75 plus pre-funded warrants for 1,600,043 shares at $3.7499, ~$30M gross; investors include Nantahala, TPG, Perceptive; Morgan Stanley agent.","ABO-801 holds FDA Orphan Drug and Fast Track designations; two completed Phase 3 trials (361 patients) missed the co-primary symptom endpoint but showed significant endoscopic gains.","Phase 3 trial planned to start Q2 2027, topline by end-2028; ~360,000 patients in the U.S. diagnosed with EoE."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-050606","json":"https://secwatch.observer/filing/0001493152-26-050606.json","markdown":"https://secwatch.observer/filing/0001493152-26-050606.md","text":"https://secwatch.observer/filing/0001493152-26-050606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315226050606/0001493152-26-050606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315226050606/form8-k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-09T11:35:25.983681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}